Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8288539 | TAKEDA PHARMS USA | Dipeptidyl peptidase inhibitors |
Mar, 2025
(10 months from now) | |
US7807689 | TAKEDA PHARMS USA | Dipeptidyl peptidase inhibitors |
Jun, 2028
(4 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6150384 | TAKEDA PHARMS USA | Pharmaceutical composition |
Jun, 2016
(7 years ago) | |
US6271243 | TAKEDA PHARMS USA | Pharmaceutical composition |
Jun, 2016
(7 years ago) | |
US6150383 | TAKEDA PHARMS USA | Pharmaceutical composition |
Jun, 2016
(7 years ago) | |
US6166042 | TAKEDA PHARMS USA | Pharmaceutical composition |
Jun, 2016
(7 years ago) | |
US6166043 | TAKEDA PHARMS USA | Pharmaceutical composition |
Jun, 2016
(7 years ago) | |
US6172090 | TAKEDA PHARMS USA | Pharmaceutical composition |
Jun, 2016
(7 years ago) | |
US6211205 | TAKEDA PHARMS USA | Pharmaceutical composition |
Jun, 2016
(7 years ago) | |
US5965584 | TAKEDA PHARMS USA | Pharmaceutical composition |
Jun, 2016
(7 years ago) | |
US6303640 | TAKEDA PHARMS USA | Pharmaceutical composition |
Aug, 2016
(7 years ago) | |
US6303661 | TAKEDA PHARMS USA | Use of dipeptidyl peptidase IV effectors for lowering the blood glucose level in mammals |
Apr, 2017
(7 years ago) | |
US7459428 | TAKEDA PHARMS USA | Method of regulating glucose metabolism, and reagents related thereto |
Feb, 2019
(5 years ago) | |
US6890898 | TAKEDA PHARMS USA | Method of regulating glucose metabolism, and reagents related thereto |
Feb, 2019
(5 years ago) | |
US7078381 | TAKEDA PHARMS USA | Method of regulating glucose metabolism, and reagents related thereto |
Feb, 2019
(5 years ago) | |
US6329404 | TAKEDA PHARMS USA | Pharmaceutical composition |
Jun, 2021
(2 years ago) | |
US8173663 | TAKEDA PHARMS USA | Dipeptidyl peptidase inhibitors |
Mar, 2025
(10 months from now) | |
US8637079 | TAKEDA PHARMS USA | Solid preparation comprising alogliptin and pioglitazone |
Jun, 2029
(5 years from now) |
Oseni is owned by Takeda Pharms Usa.
Oseni contains Alogliptin Benzoate; Pioglitazone Hydrochloride.
Oseni has a total of 18 drug patents out of which 14 drug patents have expired.
Expired drug patents of Oseni are:
Oseni was authorised for market use on 25 January, 2013.
Oseni is available in tablet;oral dosage forms.
Oseni can be used as methods of reducing the side effects of active components administered to a diabetic patient comprising administering an insulin sensitivity enhancer such as pioglitazone in combination with a biguanide such as metformin, methods of treating glycometabolism disorders comprising administering an insulin sensitivity enhancer such as pioglitazone in combination with a biguanide such as metformin, methods of treating lipid metabolism disorders comprising administering an insulin sensitivity enhancer such as pioglitazone in combination with a biguanide such as metformin, methods of treating diabetes comprising administering a dipeptidyl peptidase inhibitor and metformin, method of treating diabetes comprising administering alogliptin, methods of treating lipid metabolism and glycometabolism disorders comprising administering an insulin sensitivity enhancer such as pioglitazone in combination with an insulin secretion enhancer, methods of reducing the amount of active components administered to a diabetic patient comprising administering an insulin sensitivity enhancer such as pioglitazone in combination with a biguanide such as metformin, methods of treating diabetes comprising administering an insulin sensitivity enhancer such as pioglitazone in combination with a biguanide such as metformin, methods of reducing the side effects of active components administered to a diabetic patient comprising administering an insulin sensitivity enhancer such as pioglitazone in combination with an insulin preparation, methods of modifying glucose metabolism and treating diabetes comprising administering a dipeptidyl peptidase inhibitor and one or more other therapeutic agents such as metformin, method of treating diabetes comprising administering a compound such as alogliptin, methods of reducing the side effects of active components administered to a diabetic patient comprising administering an insulin sensitivity enhancer such as pioglitazone in combination with an insulin secretion enhancer, methods of reducing the amount of active components administered to a diabetic patient comprising administering an insulin sensitivity enhancer such as pioglitazone in combination with an insulin secretion enhancer, methods of lowering elevated post prandial blood glucose levels comprising administering a dipeptidyl peptidase inhibitor, methods of treating diabetes comprising administering an insulin sensitivity enhancer such as pioglitazone in combination with an insulin secretion enhancer.
Drug patent challenges can be filed against Oseni from 25 January, 2017.
The generics of Oseni are possible to be released after 04 June, 2029.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
M(M-177) | Apr 05, 2019 |
New Combination(NC) | Jan 25, 2016 |
New Chemical Entity Exclusivity(NCE) | Jan 25, 2018 |
Drugs and Companies using ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE ingredient
NCE-1 date: 25 January, 2017
Market Authorisation Date: 25 January, 2013
Treatment: Methods of treating lipid metabolism disorders comprising administering an insulin sensitivity enhancer such as pioglitazone in combination with a biguanide such as metformin; Methods of reducing the ...
Dosage: TABLET;ORAL